Vivek Subbiah

NYU Langone Health's Perlmutter Cancer Center has appointed Vivek Subbiah, MD, to lead its early-phase drug development and rare cancer programs. Subbiah, known for his work in early-stage oncology trials and precision medicine, will oversee efforts to bring experimental therapies to patients. The move is part of the center's push to expand clinical trial capabilities.

Oncologist Vivek Subbiah is preparing to bring personalised medicine into focus at ESMO 2026, Europe's major medical oncology congress. The oncology news outlet Oncodaily highlighted his upcoming role in framing how precision treatments — therapies tailored to a patient's tumour biology — will feature at next year's meeting. Subbiah is a well-known figure in early-phase drug development, and attention is turning to what he will present or discuss at the congress.